Juliana Muñoz-Ortiz

Juliana Muñoz-Ortiz

Auto-generated profile, based on publicly available information

Juliana Muñoz-Ortiz

Neuroscience Research Group “NeURos”, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2021 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
JMJuliana Muñoz-Ortiz
Juliana Muñoz-Ortiz
JRJuliana Reyes-Guanes
Juliana Reyes-Guanes
EZEstefanía Zapata-Bravo
Estefanía Zapata-Bravo
LMLaura Mora-Muñoz
Laura Mora-Muñoz
JRJuan Antonio Reyes-Hurtado
Juan Antonio Reyes-Hurtado
ADAlejandra de-la-Torre
Alejandra de-la-Torre
Purpose: The aim of this study was to review the scientific evidence and describe the ocular treatment-emergent adverse events (TEAEs) related to pharmacological treatment in patients with multiple sclerosis. Methods: A systematic review of literature was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines in the MEDLINE, LILACS, EMBASE, and COCHRANE databases. Articles were filtered based on title and abstract considering the selection criteria and subsequently filtered by full-text reading. The resulting articles were evaluated using the Joanna Briggs Institute Quality Tools. Study characteristics and results were extracted and presented in structured tables to conduct a narrative synthesis. Results: A total of 2852 published articles were extracted using our strategy. After removing duplicates, 2841 articles were screened based on title and abstract, 102 articles were evaluated using quality tools, and 69 articles were filtered by full-text reading. Through this search strategy, 60 articles met all the inclusion criteria and seven articles, through a search update conducted in the same manner, were included. This resulted in 67 articles meeting the inclusion criteria, of which 11 were experimental and 56 were observational. The therapies related to ocular TEAEs were alemtuzumab, amantadine, fingolimod, steroids, CTLA-4 Ig, estriol, interferon β, natalizumab, hyperbaric oxygen, rituximab, siponimod, teriflunomide, and tovaxin. Fingolimod and siponimod were commonly associated with macular edema, interferon β was associated with retinopathy, alemtuzumab was associated with thyroid eye disease, amantadine was associated with corneal edema, and steroids were associated with acute retinal necrosis. Opportunistic infections were also found, and there was one life-threatening case. Conclusions: Our search revealed different methodological assessments of the topic. However, longitudinal studies regarding ocular TEAEs related to multiple sclerosis therapy are necessary to provide evidence-based recommendations, especially in understudied regions such as Latin America and Africa. Physicians should monitor ocular symptoms in patients being treated for multiple sclerosis and consider an interdisciplinary approach. Systematic review registration: PROSPERO ID CRD42020106886

3 June 2019 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
ADAlejandra de-la-Torre
Alejandra de-la-Torre
CSClaudia T. Silva-Aldana
Claudia T. Silva-Aldana
JMJuliana Muñoz-Ortiz
Juliana Muñoz-Ortiz
LPLaura B. Piñeros-Hernández
Laura B. Piñeros-Hernández
OOOscar Otero
Oscar Otero
MAMauricio Arcos-Burgos
Mauricio Arcos-Burgos
Uveitis, defined as inflammation of the uveal tract of the eye, is a leading cause of blindness and visual impairment throughout the world. The etiology of uveitis is complex, and autoimmunity plays a major role in its pathogenesis. Intermediate uveitis (IU), a subtype of ocular inflammation, has been associated with systemic autoimmune disorders, specifically with multiple sclerosis (MS). This article reports a rare three-generation family with several members affected by IU (four siblings) and comorbid MS (two siblings fulfilling MS diagnostic criteria and a third sibling presenting some neurological symptoms). Based on the clinical findings, we captured and sequenced whole exomes of seven pedigree members (affected and unaffected). Using a recessive model of transmission with full penetrance, we applied genetic linkage analysis to define minimal critical regions (MCRs) in suggestive or nominal regions of linkage. In these MCRs, we defined functional (some pathogenic), novel, and rare mutations that segregated as homozygous in affected and heterozygous in unaffected family members. The genes harboring these mutations, including DGKI, TNFRSF10A, GNGT1, CPAMD8, and BAFF, which are expressed in both eye and brain tissues and/or are related to autoimmune diseases, provide new avenues to evaluate the inherited causes of these devastating autoimmune conditions.

1 October 2020 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
WRWilliam Rojas-Carabali
William Rojas-Carabali
PUPilar Uribe-Reina
Pilar Uribe-Reina
JMJuliana Muñoz-Ortiz
Juliana Muñoz-Ortiz
JTJuan Pablo Terreros-Dorado
Juan Pablo Terreros-Dorado
MRMaría Eugenia Ruiz-Botero
María Eugenia Ruiz-Botero
ADAlejandra de-la-Torre
Alejandra de-la-Torre
Purpose: To describe ocular surface characteristics and tests’ results in a healthy pediatric population. Methods: We performed a cross-sectional study with 60 healthy children, obtaining consent, OSDI and screen use survey and conducting ocular surface tests. Statistical univariate analysis for categorical and quantitative variables was made. To describe the correlation of the results in both eyes, we used a model of random effects. To characterize the possible profiles of device use, we applied the mixed-cluster methodology. Results: Sixty healthy children between 7 and 17 years old were evaluated. Girl’s proportion was 41.6%. Mean Ocular Surface Disease Index Score was 9.98± 8.49 points. Daily screen time was 5.59± 2.77 hours and the most popular screen was the smartphone. Mean results (with standard deviations or confidence intervals) of ocular surface tests were blink frequency while reading on paper, 6.8± 5.68 times per minute; blink frequency while reading on screen, 8.7± 7.14 times per minute; tear meniscus height, 0.19[0.18– 0.2] mm; non-invasive tear break-up time, 12.44[10.99– 13.9] seconds; nasal conjunctival redness, 0.86[0.77– 0.94]; temporal conjunctival redness, 0.96[0.87– 1.04]; tear osmolarity, 299.3[295.14– 303.45] mmol; and Schirmer test, 23.73[21.28– 26.18] mm. Lid margin was irregular in three eyes; 44.7% had thin lipid layer; lissamine green staining was positive in 70.8%; fluorescein staining was positive in 47.4%; 36.64% exhibited partial meibomian gland loss. Conclusion: Considering the scarcity of specific pediatric values of ocular surface tests, we performed a clinical investigation involving the complete pool of ocular surface tests in children. Although healthy children were included in this study, we found that all the participants had at least one abnormal result and 33.33% had dry eye disease diagnosis, according to the TFOS DEWS II. It would be relevant to carry out further multicentric studies to compare our ocular surface tests’ results with other groups of children.

1 January 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
AVAlejandra Villalobos-Pérez
Alejandra Villalobos-Pérez
JRJuliana Reyes-Guanes
Juliana Reyes-Guanes
JMJuliana Muñoz-Ortiz
Juliana Muñoz-Ortiz
MFMaria Andrea Estévez- Florez
Maria Andrea Estévez- Florez
MRMario Ramos-Santodomingo
Mario Ramos-Santodomingo
ADAlejandra de-la-Torre
Alejandra de-la-Torre
Purpose: To describe the evaluation and referral process from a group of patients with uveitis presented at a specialized uveitis center in Bogotá, Colombia. Methods: An observational descriptive cross-sectional study was performed. After applying the selection criteria, 315 clinical records were recovered. Univariate and bivariate analyses were used, reporting proportions, means and standard deviations. Results: The mean age of the sample was 45.23 years old and 63.8% of them were females. Patients were mostly referred by retina specialists, general ophthalmologists, rheumatologists, and cornea specialists. Meantime between the first ocular symptom and uveitis specialist evaluation was 2.08 years. Patients had been previously evaluated by a mean of 1.9 ophthalmologists. In 79.9% of patients, inflammation was recognized by the remittent; however, only 4.7% of patients were correctly graded according to SUN classification. At first time consultation with the uvea specialist, 52.1% of the patients arrived with an adequate infectious panel, 58.1% with an adequate rheumatologic panel, 11.6% with aqueous humor PCR study, 65.1% with an initial etiological diagnosis, 34.9% with inadequate topical treatment, and 59.6% with inadequate systemic treatment. The mean time to reach a diagnosis by the uvea specialist was 5.27 weeks (0.10 years). A diagnostic coincidence was not reached in 58.7% of the cases. Conclusion: The referral process to uveitis specialists is complex but highly relevant for those who suffer from this pathology. Health professionals must be aware of the standardized classification of the disease, the appropriate treatment according to the classification, and early referral to the uveologist with adequate laboratory tests.

1 June 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
PUPilar Uribe-Reina
Pilar Uribe-Reina
JMJuliana Muñoz-Ortiz
Juliana Muñoz-Ortiz
CGCarlos Humberto Cifuentes González
Carlos Humberto Cifuentes González
JRJuliana Reyes-Guanes
Juliana Reyes-Guanes
JTJuan Pablo Terreros-Dorado
Juan Pablo Terreros-Dorado
ADAlejandra de-la-Torre
Alejandra de-la-Torre
Purpose: To establish the prevalence of ocular involvement in a Colombian population with rheumatologic diseases. Design: Observational cross-sectional study. Methods: We included a probabilistic sample size of 797 patients who attended a rheumatologic disease center in Bogotá, Colombia. Statistical analysis with descriptive measures and Chi-square independence test between rheumatologic diseases and ophthalmological symptoms and diseases was performed. Results: Eighty-four percent of the population were women, and the mean age was 54.61± 15.64 years. The most common condition was rheumatoid arthritis (33.37%), followed by fibromyalgia (22.71%), Sjögren Syndrome (19.72%), and systemic lupus erythematosus (9.91%). Almost 7% of the patients presented polyautoimmunity. Thirty-five percent of the patients reported one or more ophthalmological symptoms, being dry eye sensation the most common (30.86%), followed by ocular pain (2.76%), red-eye, and decreased visual acuity (both 2.63%). Similarly, 21.45% of the patients presented one or more ophthalmological diagnoses, being keratoconjunctivitis sicca the most common (15.93%), followed by cataract, uveitis (1.38% each), and scleritis (1.25%). Conclusion: Almost a third of the patients reported any ocular involvement. It is crucial to be aware of the most common ophthalmic manifestations among the different rheumatologic diseases in our population, to offer early specialist referral and timely treatment.

20 June 2019 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
JFJohn E. Feliciano-Alfonso
John E. Feliciano-Alfonso
AVAndrés Vargas-Villanueva
Andrés Vargas-Villanueva
MMMaría Alejandra Marín
María Alejandra Marín
LTLaura Triviño
Laura Triviño
NCNatalia Carvajal
Natalia Carvajal
ADAlejandra de-la-Torre
Alejandra de-la-Torre
Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT. This systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group’s tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians’ awareness of antibiotic therapies, improving the health of patients with OT. PROSPERO CRD42018085468.